Indian pharma, healthcare sector record 72 deals worth USD 3.5 billion in Q3 2025: Grant Thornton Bharat
India's pharma and healthcare sector recorded a robust USD 3.5 billion across 72 transactions in the third quarter of 2025, signalling a sharp rebound in investor confidence, according to Grant Thornton Bharat’s latest Dealtracker.
The quarter also featured three IPOs worth USD 428 million and a QIP worth USD 88 million. Excluding public market moves, private deals contributed USD 3 billion across 68 transactions, it added.
The surge was driven by seven high value deals worth USD 2.6 billion, reflecting renewed investor confidence in scale and consolidation plays across pharma, biotech, and hospital segments, and mirroring the sector's strong fundamentals and growth potential.
The standout transaction of the quarter was Torrent Pharma's USD 1.4 billion acquisition of a 46 per cent stake in JB Chemicals & Pharmaceuticals, strengthening its position in high-growth therapeutic segments and chronic care markets, it added.
"Q3 marked a resurgence in deal activity, driven by a healthy mix of scale, capability, and innovation-led investments, " Grant Thornton Bharat Partner and Healthcare Industry Leader, Bhanu Prakash Kalmath S J said, according to a PTI report.
The momentum in pharma and biotech, supported by strategic consolidations, signals growing confidence in India's life sciences potential, Kalmath S J noted.
In the mergers and acquisitions (M&A) landscape, activity surged in Q3, recording 36 deals worth USD 2.5 billion, a 57 per cent rise in volumes over the previous quarter.
On the Private Equity (PE) front, the healthcare and pharmaceutical sector saw 32 deals worth USD 425 million in Q3 2025, reflecting a 3 per cent decline in volumes and a 27 per cent drop in values compared with the previous quarter.
Activity remained focused on health tech, wellness, and pharma services, with a clear preference for early and mid-stage investments, Grant Thornton Bharat said.
Next Story